Compound class:
Synthetic organic
Comment: NSC61610 is a LANCL2 modulator that was discovered using high-throughput, structure-based virtual screening [2]. It has a poor drug-like profile, passing only one of the six Lipinski-like filters. Omilancor was designed as an improved version of NSC61610 (it passes three of the Lipinski rules).
|
|
References |
1. Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J. (2016)
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. J Med Chem, 59 (22): 10113-10126. [PMID:27933891] |
2. Lu P, Hontecillas R, Horne WT, Carbo A, Viladomiu M, Pedragosa M, Bevan DR, Lewis SN, Bassaganya-Riera J. (2012)
Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2. PLoS ONE, 7 (4): e34643. [PMID:22509338] |